| Ytd | -66.27% | |
| 1y | -54.87% |
| Open | 0.94 | Prev Close | 0.94 | Low | 0.90 | High | 0.95 | Mkt Cap | 73.73M |
| Vol | 322.55K | Avg Vol | 1.43M | EPS | -0.60 | P/E | N/A | Forward P/E | -4.03 |
| Beta | 1.49 | Short Ratio | 8.06 | Inst. Own | 27.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.04 | 200-d Avg | 1.75 | 1yr Est | 10.75 |
CRDF News
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday'
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.14) per share which beat the analyst
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onv
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday
Dow gains over 150 points, NASDAQ and S&P 500 also up. Consumer discretionary shares jump 1.2%,
US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while heal
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”),
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line
Craig-Hallum analyst Albert Lowe downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Hold and l
Data Highlights from the ongoing Phase 2 trial (Data cut: March 18, 2026):In the intent-to-treat (IT
- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + s
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage
Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Resident
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001213037/000119312526248711/crdf-20260527.htm
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibit
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; i
Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday said that it filed a lawsuit against Nerviano Medical
Cardiff Oncology sued Nerviano Medical Sciences over onvansertib licensing claims as analysts backed
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.18) per share which missed the analy
Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemother
SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clini
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stag
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibit
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stag
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibit
Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, inc
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibit
Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer Appoint
Cardiff Oncology posted Phase II data for onvansertib in RAS-mutated mCRC, showing a 72% ORR versus
Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibit
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stag
Preclinical results in therapy-resistant HER2-low breast cancer models demonstrate enhanced antitumo
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Cardiff Oncology (NASDAQ: CRDF - Get Free
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage
Piper Sandler analyst Edward Tenthoff maintains Cardiff Oncology (NASDAQ:CRDF) with a Overweight
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.11) per share which beat the analyst
HC Wainwright & Co. analyst Robert Burns reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy
Cardiff Oncology shares fell 32% after a sudden CEO and CFO exit, trial strategy changes, and a nega
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibit
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improve
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibit
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.17) per share which beat the analyst
HC Wainwright & Co. analyst Robert Burns maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy
Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal can